person · Reporting owner
Hall Patricia Hemingway
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CARDINAL HEALTH INCCAH · Entity 3014 | Director | April 15, 2026 | April 17, 2026 |
| HALLIBURTON COHAL · Entity 3141 | Director | February 28, 2022 | March 01, 2022 |
| ManpowerGroup Inc.MAN · Entity 1769 | Director | January 01, 2025 | January 03, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CARDINAL HEALTH INC
Report date April 15, 2026 · Filed April 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 28,645 |
Reported balance
After 2026-04-15 transaction · row 1
1 source rowRow 1 · 2026-04-15 · Grant · Acquired 381 · Balance 28,645 F2: Price is closing share price on March 20, 2026, which is the date on which Ms. Hemingway Hall was elevated to Chair of the Board. F1: Ms. Hemingway Hall received a grant of additional RSUs in connection with her elevation to Chair of the Board, effective March 20, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Ms. Hemingway Hall received a grant of additional RSUs in connection with her elevation to Chair of the Board, effective March 20, 2026.
F2: Price is closing share price on March 20, 2026, which is the date on which Ms. Hemingway Hall was elevated to Chair of the Board.
HALLIBURTON CO
Report date February 28, 2022 · Filed March 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,299 |
Reported balance
After 2022-02-28 transaction · row 1
1 source rowRow 1 · 2022-02-28 · Exercise / conversion · Acquired 762 · Balance 6,299 F1: Vesting of 25% of restricted stock units granted on February 28, 2019. |
| 02/2019 Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 762 |
Reported balance
After 2022-02-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-02-28 · Exercise / conversion · Disposed 762 · Balance 762 F2: Each restricted stock unit represents a right to receive one share of the Company's common stock. F3: The restricted stock units vest in four equal annual installments beginning with the first anniversary of the award. Shares will be delivered to the reporting person either upon vesting or, if reporting person elected to defer receipt, following cessation as a director. |
| 08/2019 Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 4,014 |
Reported balance
Holding disclosure · report date 2022-02-28 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 4,014 F2: Each restricted stock unit represents a right to receive one share of the Company's common stock. F3: The restricted stock units vest in four equal annual installments beginning with the first anniversary of the award. Shares will be delivered to the reporting person either upon vesting or, if reporting person elected to defer receipt, following cessation as a director. |
| 12/2020 Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 12,425.48 |
Reported balance
Holding disclosure · report date 2022-02-28 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 12,425.48 F2: Each restricted stock unit represents a right to receive one share of the Company's common stock. F4: The restricted stock units vest in one year on the first anniversary of the award. Shares will be delivered to the reporting person either upon vesting, or if reporting person elected to defer receipt, following cessation as a director. |
| 12/2021 Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 7,849 |
Reported balance
Holding disclosure · report date 2022-02-28 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 7,849 F2: Each restricted stock unit represents a right to receive one share of the Company's common stock. F4: The restricted stock units vest in one year on the first anniversary of the award. Shares will be delivered to the reporting person either upon vesting, or if reporting person elected to defer receipt, following cessation as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: Vesting of 25% of restricted stock units granted on February 28, 2019.
F2: Each restricted stock unit represents a right to receive one share of the Company's common stock.
F3: The restricted stock units vest in four equal annual installments beginning with the first anniversary of the award. Shares will be delivered to the reporting person either upon vesting or, if reporting person elected to defer receipt, following cessation as a director.
F4: The restricted stock units vest in one year on the first anniversary of the award. Shares will be delivered to the reporting person either upon vesting, or if reporting person elected to defer receipt, following cessation as a director.
ManpowerGroup Inc.
Report date January 01, 2025 · Filed January 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,659 |
Ending reported balance
After 2025-01-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-01-01 · Exercise / conversion · Acquired 2,013 · Balance 18,540 F1: Settlement of shares of deferred stock in shares of ManpowerGroup common stock on a 1 for 1 basis. Row 2 · 2025-01-01 · Grant · Acquired 3,119 · Balance 21,659 F2: Annual grant of restricted stock under the 2011 Equity Incentive Plan of the Company (the "Plan") and the Terms and Conditions Regarding the Grant of Awards to Non-Employee Directors under the Plan (the "Terms and Conditions"). F3: The shares of restricted stock will vest in quarterly installments on the last day of each calendar quarter during 2025. F4: Represents the Market Price (as defined in the Plan) on the last trading day of 2024. |
| Deferred Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,013 |
Reported balance
After 2025-01-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-01-01 · Grant · Acquired 85 · Balance 2,013 F5: The shares of deferred stock are fully vested on the date of grant and were settled in shares of ManpowerGroup common stock on a 1 for 1 basis on January 1, 2025. F6: Receipt of deferred stock under the Plan and the Terms and Conditions in lieu of dividends. F7: Represents the Average Trading Price (as defined in the Terms and Conditions). |
| Deferred Stock UnitsSEC Table II · derivative / convertible security · Expires 2025-01-01 | Direct | 0 |
Reported balance
After 2025-01-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-01-01 · Exercise / conversion · Acquired 2,013 · Balance 0 F5: The shares of deferred stock are fully vested on the date of grant and were settled in shares of ManpowerGroup common stock on a 1 for 1 basis on January 1, 2025. F1: Settlement of shares of deferred stock in shares of ManpowerGroup common stock on a 1 for 1 basis. |
| Deferred Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,992 |
Reported balance
After 2025-01-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-01-01 · Grant · Acquired 127 · Balance 2,992 F8: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2027 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. F6: Receipt of deferred stock under the Plan and the Terms and Conditions in lieu of dividends. F7: Represents the Average Trading Price (as defined in the Terms and Conditions). |
Filing footnotes · ownership attribution and instrument terms
F1: Settlement of shares of deferred stock in shares of ManpowerGroup common stock on a 1 for 1 basis.
F2: Annual grant of restricted stock under the 2011 Equity Incentive Plan of the Company (the "Plan") and the Terms and Conditions Regarding the Grant of Awards to Non-Employee Directors under the Plan (the "Terms and Conditions").
F3: The shares of restricted stock will vest in quarterly installments on the last day of each calendar quarter during 2025.
F4: Represents the Market Price (as defined in the Plan) on the last trading day of 2024.
F5: The shares of deferred stock are fully vested on the date of grant and were settled in shares of ManpowerGroup common stock on a 1 for 1 basis on January 1, 2025.
F6: Receipt of deferred stock under the Plan and the Terms and Conditions in lieu of dividends.
F7: Represents the Average Trading Price (as defined in the Terms and Conditions).
F8: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2027 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CELGENE CORP /DE/
Report date November 20, 2019 · Filed November 22, 2019
Section 16 reporting ended · disclosed 2019-11-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $91.10 · Expires 2028-04-17 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-11-20 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $77.38 · Expires 2028-06-13 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-11-20 · Disposition to issuer · Disposed 13,266 · Balance 0 F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1: This option was fully exercisable. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-11-20 · Disposition to issuer · Disposed 1,454 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F4: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-11-20 · Disposition to issuer · Disposed 4,756 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F4: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was fully exercisable.
F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
F3: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock.
F4: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerRestricted Stock Unit · Derivative | 4,756 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001364 · form4-11222019_071116.xml · derivative · entry 4 Hall Patricia Hemingway · CIK 0001517890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,756 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F4 · price: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F4 · derivative.exercise_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F4 · derivative.expiration_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerRestricted Stock Unit · Derivative | 1,454 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001364 · form4-11222019_071116.xml · derivative · entry 3 Hall Patricia Hemingway · CIK 0001517890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,454 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F4 · price: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F4 · derivative.exercise_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F4 · derivative.expiration_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 13,266 | $0.00 Strike: $77.38 | $0.00 |
DisclosureSEC source: 0001415889-19-001364 · form4-11222019_071116.xml · derivative · entry 2 Hall Patricia Hemingway · CIK 0001517890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,266 shares Expires 2028-06-13 F2 · price: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1 · derivative.exercise_date: This option was fully exercisable. F2 · derivative.exercise_date: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $91.10 | $0.00 |
DisclosureSEC source: 0001415889-19-001364 · form4-11222019_071116.xml · derivative · entry 1 Hall Patricia Hemingway · CIK 0001517890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2028-04-17 F2 · price: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1 · derivative.exercise_date: This option was fully exercisable. F2 · derivative.exercise_date: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 12, 2019 Filed Nov 13, 2019 21:16 UTC | CARDINAL HEALTH INC CAH · Entity 3014 | GrantCommon Shares | 3,424 | $0.00 | $0.00 |
DisclosureSEC source: 0000721371-19-000146 · wf-form4_157367979456640.xml · nonDerivative · entry 1 Hall Patricia Hemingway · CIK 0001517890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,146 F1 · shares: Grant of restricted share units that will vest on November 12, 2020, except if the 2020 Annual Meeting of Shareholders is prior to November 12, 2020, then the restricted share units will vest on the date of the 2020 Annual Meeting of Shareholders. Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 20:32 UTC | HALLIBURTON CO HAL · Entity 3141 | Grant08/2019 Restricted Stock Units · Derivative | 8,027 | $0.00 | $0.00 |
DisclosureSEC source: 0000045012-19-000124 · edgar.xml · derivative · entry 1 Hall Patricia Hemingway · CIK 0001517890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,027 Underlying: Common Stock · 8,027 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a right to receive one share of the Company's common stock. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning with the first anniversary of the award. Shares will be delivered to the reporting person either upon vesting, or if reporting person elected to defer receipt, following cessation as a director. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning with the first anniversary of the award. Shares will be delivered to the reporting person either upon vesting, or if reporting person elected to defer receipt, following cessation as a director. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantRestricted Stock Unit · Derivative | 4,756 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000662 · form4-06052019_040611.xml · derivative · entry 1 Hall Patricia Hemingway · CIK 0001517890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,756 Underlying: Common Stock · 4,756 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F2 · derivative.exercise_date: The restricted stock units will vest in three annual installments as follows: 1,585 shares on June 3, 2020; 1,585 shares on June 3, 2021; and 1,586 shares on June 3, 2022. Vested shares will be delivered to the reporting person promptly after the vesting date. F2 · derivative.expiration_date: The restricted stock units will vest in three annual installments as follows: 1,585 shares on June 3, 2020; 1,585 shares on June 3, 2021; and 1,586 shares on June 3, 2022. Vested shares will be delivered to the reporting person promptly after the vesting date. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 20:12 UTC | HALLIBURTON CO HAL · Entity 3141 | GrantCommon Stock · Derivative | 3,048 | $0.00 | $0.00 |
DisclosureSEC source: 0000045012-19-000061 · edgar.xml · derivative · entry 1 Hall Patricia Hemingway · CIK 0001517890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,048 Underlying: Common Stock · 3,048 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a right to receive one share of the Company's common stock. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning with the first anniversary of the award. Shares will be delivered to the reporting person either upon vesting, or if reporting person elected to defer receipt, following cessation as a director. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning with the first anniversary of the award. Shares will be delivered to the reporting person either upon vesting, or if reporting person elected to defer receipt, following cessation as a director. Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 21:52 UTC | ManpowerGroup Inc. MAN · Entity 1769 | Exercise / conversionDeferred Stock · Derivative | 1,766 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000871763-19-000020 · wf-form4_154655235656868.xml · derivative · entry 6 Hall Patricia Hemingway · CIK 0001517890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,766 shares Expires 2019-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2019 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. F1 · price: Settlement of shares of deferred stock in shares of ManpowerGroup common stock on a 1 for 1 basis. Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 21:52 UTC | ManpowerGroup Inc. MAN · Entity 1769 | GrantDeferred Stock · Derivative | 40 | $87.98 | $3,519.20 |
DisclosureSEC source: 0000871763-19-000020 · wf-form4_154655235656868.xml · derivative · entry 5 Hall Patricia Hemingway · CIK 0001517890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,766 Underlying: Common Stock · 40 shares Expires not disclosed F9 · derivative.exercise_price: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2019 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. F6 · kind: Receipt of deferred stock under the Plan and the Terms and Conditions in lieu of dividends. F7 · price: Represents the Average Trading Price (as defined in the Terms and Conditions). F9 · derivative.exercise_date: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2019 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. F9 · derivative.expiration_date: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2019 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 21:52 UTC | ManpowerGroup Inc. MAN · Entity 1769 | GrantDeferred Stock · Derivative | 38 | $87.98 | $3,343.24 |
DisclosureSEC source: 0000871763-19-000020 · wf-form4_154655235656868.xml · derivative · entry 4 Hall Patricia Hemingway · CIK 0001517890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,697 Underlying: Common Stock · 38 shares Expires not disclosed F8 · derivative.exercise_price: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2020 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. F6 · kind: Receipt of deferred stock under the Plan and the Terms and Conditions in lieu of dividends. F7 · price: Represents the Average Trading Price (as defined in the Terms and Conditions). F8 · derivative.exercise_date: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2020 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. F8 · derivative.expiration_date: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2020 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 21:52 UTC | ManpowerGroup Inc. MAN · Entity 1769 | GrantDeferred Stock · Derivative | 29 | $87.98 | $2,551.42 |
DisclosureSEC source: 0000871763-19-000020 · wf-form4_154655235656868.xml · derivative · entry 3 Hall Patricia Hemingway · CIK 0001517890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,298 Underlying: Common Stock · 29 shares Expires not disclosed F5 · derivative.exercise_price: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2021 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. F6 · kind: Receipt of deferred stock under the Plan and the Terms and Conditions in lieu of dividends. F7 · price: Represents the Average Trading Price (as defined in the Terms and Conditions). F5 · derivative.exercise_date: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2021 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. F5 · derivative.expiration_date: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2021 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 21:52 UTC | ManpowerGroup Inc. MAN · Entity 1769 | GrantDeferred Stock · Derivative | 2,469 | $64.80 | $159,991.20 |
DisclosureSEC source: 0000871763-19-000020 · wf-form4_154655235656868.xml · derivative · entry 2 Hall Patricia Hemingway · CIK 0001517890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,469 Underlying: Common Stock · 2,469 shares Expires not disclosed F2 · derivative.exercise_price: These shares of deferred stock vest in quarterly installments on the last day of each calendar quarter during 2019 and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2022 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions (as defined below). F3 · kind: Annual grant of deferred stock under the 2011 Equity Incentive Plan of the Company (the "Plan") and the Terms and Conditions Regarding the Grant of Awards to Non-Employee Directors under the Plan (the "Terms and Conditions"). F4 · price: Represents the Market Price (as defined in the Plan) on the last trading day of 2018. F2 · derivative.exercise_date: These shares of deferred stock vest in quarterly installments on the last day of each calendar quarter during 2019 and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2022 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions (as defined below). F2 · derivative.expiration_date: These shares of deferred stock vest in quarterly installments on the last day of each calendar quarter during 2019 and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2022 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions (as defined below). Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 21:52 UTC | ManpowerGroup Inc. MAN · Entity 1769 | Exercise / conversionCommon Stock | 1,766 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000871763-19-000020 · wf-form4_154655235656868.xml · nonDerivative · entry 1 Hall Patricia Hemingway · CIK 0001517890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Settlement of shares of deferred stock in shares of ManpowerGroup common stock on a 1 for 1 basis. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 22:23 UTC | CARDINAL HEALTH INC CAH · Entity 3014 | GrantCommon Shares | 3,164 | $0.00 | $0.00 |
DisclosureSEC source: 0000721371-18-000122 · wf-form4_154214777090584.xml · nonDerivative · entry 1 Hall Patricia Hemingway · CIK 0001517890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,722 F1 · shares: Grant of restricted share units that will vest on November 9, 2019, except if the 2019 Annual Meeting of Shareholders is prior to November 9, 2019, then the restricted share units will vest on the date of the 2019 Annual Meeting of Shareholders. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 16:15 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantRestricted Stock Unit · Derivative | 1,454 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000937 · form4-06152018_010626.xml · derivative · entry 2 Hall Patricia Hemingway · CIK 0001517890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,454 Underlying: Common Stock · 1,454 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F5 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F4 · derivative.exercise_date: The restricted stock units will vest in three annual installments as follows: 484 shares on June 13, 2019; 485 shares on June 13, 2020; and 485 shares on June 13, 2021. The reporting person has elected to defer receipt of the 1,454 shares until June 13, 2021. F4 · derivative.expiration_date: The restricted stock units will vest in three annual installments as follows: 484 shares on June 13, 2019; 485 shares on June 13, 2020; and 485 shares on June 13, 2021. The reporting person has elected to defer receipt of the 1,454 shares until June 13, 2021. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 16:15 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 13,266 | $0.00 Strike: $77.38 | $0.00 |
DisclosureSEC source: 0001415889-18-000937 · form4-06152018_010626.xml · derivative · entry 1 Hall Patricia Hemingway · CIK 0001517890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,266 Underlying: Common Stock · 13,266 shares Expires 2028-06-13 F2 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: Option is immediately exercisable and will vest on the earlier of June 13, 2019 or the day preceding the date of the next annual stockholder meeting. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 22:03 UTC | ManpowerGroup Inc. MAN · Entity 1769 | Exercise / conversionDeferred Stock · Derivative | 2,095 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000871763-18-000022 · wf-form4_151501702204149.xml · derivative · entry 6 Hall Patricia Hemingway · CIK 0001517890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,095 shares Expires 2018-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2018 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. F1 · price: Settlement of shares of deferred stock in shares of ManpowerGroup common stock on a 1 for 1 basis. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 22:03 UTC | ManpowerGroup Inc. MAN · Entity 1769 | GrantDeferred Stock · Derivative | 33 | $114.54 | $3,779.82 |
DisclosureSEC source: 0000871763-18-000022 · wf-form4_151501702204149.xml · derivative · entry 5 Hall Patricia Hemingway · CIK 0001517890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,095 Underlying: Common Stock · 33 shares Expires not disclosed F9 · derivative.exercise_price: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2018 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. F6 · kind: Receipt of deferred stock under the Plan and the Terms and Conditions in lieu of dividends. F7 · price: Represents the Average Trading Price (as defined in the Terms and Conditions). F9 · derivative.exercise_date: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2018 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. F9 · derivative.expiration_date: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2018 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 22:03 UTC | ManpowerGroup Inc. MAN · Entity 1769 | GrantDeferred Stock · Derivative | 27 | $114.54 | $3,092.58 |
DisclosureSEC source: 0000871763-18-000022 · wf-form4_151501702204149.xml · derivative · entry 4 Hall Patricia Hemingway · CIK 0001517890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,659 Underlying: Common Stock · 27 shares Expires not disclosed F8 · derivative.exercise_price: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2020 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. F6 · kind: Receipt of deferred stock under the Plan and the Terms and Conditions in lieu of dividends. F7 · price: Represents the Average Trading Price (as defined in the Terms and Conditions). F8 · derivative.exercise_date: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2020 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. F8 · derivative.expiration_date: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2020 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 22:03 UTC | ManpowerGroup Inc. MAN · Entity 1769 | GrantDeferred Stock · Derivative | 28 | $114.54 | $3,207.12 |
DisclosureSEC source: 0000871763-18-000022 · wf-form4_151501702204149.xml · derivative · entry 3 Hall Patricia Hemingway · CIK 0001517890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,726 Underlying: Common Stock · 28 shares Expires not disclosed F5 · derivative.exercise_price: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2019 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. F6 · kind: Receipt of deferred stock under the Plan and the Terms and Conditions in lieu of dividends. F7 · price: Represents the Average Trading Price (as defined in the Terms and Conditions). F5 · derivative.exercise_date: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2019 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. F5 · derivative.expiration_date: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2019 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 22:03 UTC | ManpowerGroup Inc. MAN · Entity 1769 | GrantDeferred Stock · Derivative | 1,269 | $126.11 | $160,033.59 |
DisclosureSEC source: 0000871763-18-000022 · wf-form4_151501702204149.xml · derivative · entry 2 Hall Patricia Hemingway · CIK 0001517890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,269 Underlying: Common Stock · 1,269 shares Expires not disclosed F2 · derivative.exercise_price: These shares of deferred stock vest in quarterly installments on the last day of each calendar quarter during 2018 and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2021 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions (as defined below). F3 · kind: Annual grant of deferred stock under the 2011 Equity Incentive Plan of the Company (the "Plan") and the Terms and Conditions Regarding the Grant of Awards to Non-Employee Directors under the Plan (the "Terms and Conditions"). F4 · price: Represents the Market Price (as defined in the Plan) on the last trading day of 2017. F2 · derivative.exercise_date: These shares of deferred stock vest in quarterly installments on the last day of each calendar quarter during 2018 and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2021 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions (as defined below). F2 · derivative.expiration_date: These shares of deferred stock vest in quarterly installments on the last day of each calendar quarter during 2018 and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2021 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions (as defined below). Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 22:03 UTC | ManpowerGroup Inc. MAN · Entity 1769 | Exercise / conversionCommon Stock | 2,095 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000871763-18-000022 · wf-form4_151501702204149.xml · nonDerivative · entry 1 Hall Patricia Hemingway · CIK 0001517890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,116 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Settlement of shares of deferred stock in shares of ManpowerGroup common stock on a 1 for 1 basis. Read SEC document |
| December 04, 2017 Filed Dec 5, 2017 21:33 UTC | ManpowerGroup Inc. MAN · Entity 1769 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000871763-17-000122 · wf-form4_151250956967733.xml · nonDerivative · entry 2 Hall Patricia Hemingway · CIK 0001517890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,021 Read SEC document |
| December 04, 2017 Filed Dec 5, 2017 21:33 UTC | ManpowerGroup Inc. MAN · Entity 1769 | SaleCommon Stock | 3,000 | $127.54 | $382,620.00 |
DisclosureSEC source: 0000871763-17-000122 · wf-form4_151250956967733.xml · nonDerivative · entry 1 Hall Patricia Hemingway · CIK 0001517890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,021 F1 · price: This price is the weighted average price. The prices received actually ranged from $127.46 to $127.68. Upon request, the reporting person will provide to the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price within this range. Read SEC document |
| November 08, 2017 Filed Nov 9, 2017 22:45 UTC | CARDINAL HEALTH INC CAH · Entity 3014 | GrantCommon Shares | 2,623 | $0.00 | $0.00 |
DisclosureSEC source: 0000721371-17-000165 · wf-form4_151026751781957.xml · nonDerivative · entry 1 Hall Patricia Hemingway · CIK 0001517890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,558 F1 · shares: Grant of restricted share units that will vest on November 8, 2018, except if the 2018 Annual Meeting of Shareholders is prior to November 8, 2018, then restricted share units will vest on the date of the 2018 Annual Meeting of Shareholders. Read SEC document |
| January 01, 2017 Filed Jan 4, 2017 21:55 UTC | ManpowerGroup Inc. MAN · Entity 1769 | GrantDeferred Stock · Derivative | 37 | $76.72 | $2,838.64 |
DisclosureSEC source: 0000871763-17-000024 · wf-form4_148356690640774.xml · derivative · entry 6 Hall Patricia Hemingway · CIK 0001517890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,698 Underlying: Common Stock · 37 shares Expires not disclosed F9 · derivative.exercise_price: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2019 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. F3 · kind: Receipt of deferred stock under the Plan and the Terms and Conditions in lieu of dividends. F4 · price: Represents the Average Trading Price (as defined in the Terms and Conditions). F9 · derivative.exercise_date: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2019 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. F9 · derivative.expiration_date: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2019 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. Read SEC document |
| January 01, 2017 Filed Jan 4, 2017 21:55 UTC | ManpowerGroup Inc. MAN · Entity 1769 | GrantDeferred Stock · Derivative | 45 | $76.72 | $3,452.40 |
DisclosureSEC source: 0000871763-17-000024 · wf-form4_148356690640774.xml · derivative · entry 5 Hall Patricia Hemingway · CIK 0001517890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,062 Underlying: Common Stock · 45 shares Expires not disclosed F8 · derivative.exercise_price: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2018 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. F3 · kind: Receipt of deferred stock under the Plan and the Terms and Conditions in lieu of dividends. F4 · price: Represents the Average Trading Price (as defined in the Terms and Conditions). F8 · derivative.exercise_date: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2018 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. F8 · derivative.expiration_date: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2018 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. Read SEC document |
| January 01, 2017 Filed Jan 4, 2017 21:55 UTC | ManpowerGroup Inc. MAN · Entity 1769 | GrantDeferred Stock · Derivative | 1,632 | $88.87 | $145,035.84 |
DisclosureSEC source: 0000871763-17-000024 · wf-form4_148356690640774.xml · derivative · entry 4 Hall Patricia Hemingway · CIK 0001517890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,632 Underlying: Common Stock · 1,632 shares Expires not disclosed F5 · derivative.exercise_price: These shares of deferred stock vest in quarterly installments on the last day of each calendar quarter during 2017 and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2020 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions (as defined below). F6 · kind: Grant of deferred stock under the 2011 Equity Incentive Plan of the Company (the "Plan") and the Terms and Conditions Regarding the Grant of Awards to Non-Employee Directors under the Plan (the "Terms and Conditions") F7 · price: Represents the Market Price (as defined in the Plan) on the last trading day of 2016. F5 · derivative.exercise_date: These shares of deferred stock vest in quarterly installments on the last day of each calendar quarter during 2017 and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2020 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions (as defined below). F5 · derivative.expiration_date: These shares of deferred stock vest in quarterly installments on the last day of each calendar quarter during 2017 and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2020 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions (as defined below). Read SEC document |
| January 01, 2017 Filed Jan 4, 2017 21:55 UTC | ManpowerGroup Inc. MAN · Entity 1769 | Exercise / conversionDeferred Stock · Derivative | 1,352 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000871763-17-000024 · wf-form4_148356690640774.xml · derivative · entry 3 Hall Patricia Hemingway · CIK 0001517890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,352 shares Expires 2017-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2017 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. F1 · price: Settlment of shares of deferred stock in shares of ManpowerGroup Inc. common stock on a 1 for 1 basis. Read SEC document |
| January 01, 2017 Filed Jan 4, 2017 21:55 UTC | ManpowerGroup Inc. MAN · Entity 1769 | GrantDeferred Stock · Derivative | 30 | $76.72 | $2,301.60 |
DisclosureSEC source: 0000871763-17-000024 · wf-form4_148356690640774.xml · derivative · entry 2 Hall Patricia Hemingway · CIK 0001517890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,352 Underlying: Common Stock · 30 shares Expires not disclosed F2 · derivative.exercise_price: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2017 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. F3 · kind: Receipt of deferred stock under the Plan and the Terms and Conditions in lieu of dividends. F4 · price: Represents the Average Trading Price (as defined in the Terms and Conditions). F2 · derivative.exercise_date: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2017 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. F2 · derivative.expiration_date: The shares of deferred stock are fully vested on the date of grant and will be settled in shares of ManpowerGroup common stock on a 1 for 1 basis on the earlier of January 1, 2017 or within 30 days after the reporting person's termination of service as a director, except as otherwise provided in the Terms and Conditions. Read SEC document |
| January 01, 2017 Filed Jan 4, 2017 21:55 UTC | ManpowerGroup Inc. MAN · Entity 1769 | Exercise / conversionCommon Stock | 1,352 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000871763-17-000024 · wf-form4_148356690640774.xml · nonDerivative · entry 1 Hall Patricia Hemingway · CIK 0001517890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,021 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Settlment of shares of deferred stock in shares of ManpowerGroup Inc. common stock on a 1 for 1 basis. Read SEC document |
| November 03, 2016 Filed Nov 7, 2016 13:19 UTC | CARDINAL HEALTH INC CAH · Entity 3014 | GrantCommon Shares | 2,447 | $0.00 | $0.00 |
DisclosureSEC source: 0000721371-16-000342 · wf-form4_147852476426108.xml · nonDerivative · entry 1 Hall Patricia Hemingway · CIK 0001517890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,935 F1 · shares: Grant of restricted share units that will vest on November 3, 2017, except if the 2017 Annual Meeting of Shareholders is prior to November 3, 2017, then the restricted share units will vest on the date of the 2017 Annual Meeting of Shareholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.